Compare Stocks: ONC, SNY, GSK, and ARGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$872.58 -1.1%	$874.71	$631.47 ▼ $953.58	$55.21B	0.45	281,755 shs	256,730 shs
GSK GSK	$52.02 -2.3%	$51.73	$36.75 ▼ $61.69	$107.65B	0.35	4.29 million shs	6.11 million shs
ONC BeOne Medicines	$322.08 -1.6%	$293.39	$253.95 ▼ $385.22	$35.90B	0.49	366,485 shs	214,117 shs
SNY Sanofi	$42.89 -4.4%	$43.46	$40.89 ▼ $52.68	$108.74B	0.34	2.98 million shs	10.20 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+1.18%	+3.62%	-3.28%	+12.90%	+47.39%
GSK GSK	-1.17%	+4.69%	+0.53%	+1.43%	+40.84%
ONC BeOne Medicines	-0.98%	+2.28%	+12.83%	+10.82%	+7.02%
SNY Sanofi	-1.52%	+2.42%	+3.27%	-3.71%	-9.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$872.58 -1.1%	$874.71	$631.47 ▼ $953.58	$55.21B	0.45	281,755 shs	256,730 shs
GSK GSK	$52.02 -2.3%	$51.73	$36.75 ▼ $61.69	$107.65B	0.35	4.29 million shs	6.11 million shs
ONC BeOne Medicines	$322.08 -1.6%	$293.39	$253.95 ▼ $385.22	$35.90B	0.49	366,485 shs	214,117 shs
SNY Sanofi	$42.89 -4.4%	$43.46	$40.89 ▼ $52.68	$108.74B	0.34	2.98 million shs	10.20 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	+1.18%	+3.62%	-3.28%	+12.90%	+47.39%
GSK GSK	-1.17%	+4.69%	+0.53%	+1.43%	+40.84%
ONC BeOne Medicines	-0.98%	+2.28%	+12.83%	+10.82%	+7.02%
SNY Sanofi	-1.52%	+2.42%	+3.27%	-3.71%	-9.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.92	Moderate Buy	$1,056.89	21.12% Upside
GSK GSK	2.10	Hold	$53.00	1.89% Upside
ONC BeOne Medicines	2.88	Moderate Buy	$394.00	22.33% Upside
SNY Sanofi	2.47	Hold	$49.50	15.41% Upside

Current Analyst Ratings Breakdown

Latest ONC, SNY, GSK, and ARGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	GSK GSK	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
7/29/2026	GSK GSK	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
7/28/2026	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$1,000.00 ➝ $1,050.00
7/27/2026	ARGX argenex	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$867.00 ➝ $932.00
7/27/2026	ONC BeOne Medicines	Nomura Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/24/2026	ARGX argenex	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$1,014.00 ➝ $1,037.00
7/24/2026	ARGX argenex	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$945.00 ➝ $1,025.00
7/24/2026	ARGX argenex	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,135.00 ➝ $1,185.00
7/24/2026	ARGX argenex	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$944.00 ➝ $932.00
7/24/2026	GSK GSK	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral
7/23/2026	ARGX argenex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)

(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$5.23B	10.44	$21.34 per share	40.89	$134.54 per share	6.49
GSK GSK	$33.20B	3.17	$5.82 per share	8.94	$10.32 per share	5.04
ONC BeOne Medicines	$5.34B	6.61	$3.81 per share	84.55	$39.77 per share	8.10
SNY Sanofi	$49.35B	2.11	$6.65 per share	6.45	$33.26 per share	1.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$26.04	33.51	24.48	1.13	32.19%	43.59%	36.66%	N/A
GSK GSK	$7.54B	$3.20	16.27	10.08	3.42	14.56%	43.79%	11.61%	N/A
ONC BeOne Medicines	$286.93M	$4.47	72.05	30.36	N/A	8.94%	12.06%	6.69%	8/5/2026 (Confirmed)
SNY Sanofi	$8.84B	$3.58	11.98	8.26	1.15	16.95%	13.39%	7.58%	7/30/2026 (Estimated)

Latest ONC, SNY, GSK, and ARGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2026	Q2 2026	SNY Sanofi	$1.10	$1.1930	+$0.0930	$0.17	$12.44 billion	$14.04 billion
7/21/2026	Q2 2026	ARGX argenex	$5.86	$7.32	+$1.46	$7.32	$1.45 billion	$1.54 billion
5/7/2026	Q1 2026	ARGX argenex	$5.74	$5.52	-$0.22	$5.52	$1.44 billion	$1.31 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
GSK GSK	$1.77	3.40%	-7.86%	55.31%	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
SNY Sanofi	$1.76	4.10%	+6.46%	49.16%	N/A

Latest ONC, SNY, GSK, and ARGX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	GSK GSK	quarterly	$0.4515	3.36%	8/14/2026	8/14/2026	10/8/2026
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.12	4.89
GSK GSK	0.80	0.79	0.52
ONC BeOne Medicines	0.20	3.64	3.27
SNY Sanofi	0.17	1.01	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
GSK GSK	15.74%
ONC BeOne Medicines	48.55%
SNY Sanofi	14.03%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
GSK GSK	10.00%
ONC BeOne Medicines	6.19%
SNY Sanofi	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.56 million	61.04 million	Optionable
GSK GSK	66,841	2.02 billion	1.82 billion	Optionable
ONC BeOne Medicines	12,000	109.72 million	102.93 million	N/A
SNY Sanofi	74,846	2.42 billion	2.40 billion	Optionable

ONC, SNY, GSK, and ARGX Headlines

Recent News About These Companies

Sanofi says weak decision-making hurt pipeline, promises more disciplined R&D

3 hours ago | msn.com

Press Release: Sanofi’s half-year financial report for 2026

July 30 at 2:08 PM | markets.businessinsider.com

Sanofi Q2 Business Earnings, Sales Rise; Raises 2026 Sales Guidance

July 30 at 2:08 PM | finance.yahoo.com

Sanofi Beats on Q2 Earnings & Sales, Stock Down on Pipeline Setbacks

July 30 at 1:06 PM | zacks.com

Sanofi Sees Unusually Large Options Volume (NASDAQ:SNY)

July 30 at 10:59 AM | marketbeat.com

Sanofi Q2 Earnings Call Highlights

July 30 at 9:03 AM | marketbeat.com

Sanofi beats Q2 growth expectations on Dupixent sales surge

July 30 at 8:14 AM | seekingalpha.com

Strategic Investment Advisors MI Buys New Holdings in Sanofi $SNY

July 30 at 5:51 AM | marketbeat.com

Sanofi Raises Guidance as New CEO Looks to Revamp Drug Pipeline

July 30 at 1:44 AM | wsj.com

Sanofi raises sales outlook on Dupixent strength in boost for new CEO

July 30 at 1:34 AM | reuters.com

Redwood Grove Capital LLC Cuts Stock Position in Sanofi $SNY

July 29 at 5:51 AM | marketbeat.com

Regal Partners Ltd Buys 633,782 Shares of Sanofi $SNY

July 29 at 5:51 AM | marketbeat.com

Maverick Capital Ltd. Purchases Shares of 24,581 Sanofi $SNY

July 29 at 5:43 AM | marketbeat.com

Bank of New York Mellon Corp Grows Holdings in Sanofi $SNY

July 29 at 3:27 AM | marketbeat.com

ADAR1 Capital Management LLC Purchases 253,465 Shares of Sanofi $SNY

July 29 at 3:11 AM | marketbeat.com

Sei Investments Co. Sells 27,582 Shares of Sanofi $SNY

July 28 at 4:55 AM | marketbeat.com

Cetera Investment Advisers Buys 43,135 Shares of Sanofi $SNY

July 28 at 3:12 AM | marketbeat.com

Hsbc Holdings PLC Sells 98,228 Shares of Sanofi $SNY

July 24, 2026 | marketbeat.com

Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO

July 24, 2026 | wsj.com

Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

July 24, 2026 | globenewswire.com

Sanofi (SNY) to Post Quarterly Earnings on Thursday

July 23, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ONC, SNY, GSK, and ARGX Company Descriptions

argenex NASDAQ:ARGX

$872.58 -9.98 (-1.13%)

Closing price 04:00 PM Eastern

Extended Trading

$873.00 +0.41 (+0.05%)

As of 07:34 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

GSK NYSE:GSK

$52.02 -1.20 (-2.26%)

Closing price 03:59 PM Eastern

Extended Trading

$51.78 -0.23 (-0.44%)

As of 07:34 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

BeOne Medicines NASDAQ:ONC

$322.08 -5.13 (-1.57%)

Closing price 04:00 PM Eastern

Extended Trading

$319.84 -2.24 (-0.70%)

As of 07:34 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Sanofi NASDAQ:SNY

$42.89 -1.96 (-4.37%)

Closing price 04:00 PM Eastern

Extended Trading

$43.07 +0.18 (+0.42%)

As of 07:08 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ONC, SNY, GSK, and ARGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ONC, SNY, GSK, and ARGX Earnings

Compare Dividends

Latest ONC, SNY, GSK, and ARGX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ONC, SNY, GSK, and ARGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ONC, SNY, GSK, and ARGX Company Descriptions

argenex NASDAQ:ARGX

GSK NYSE:GSK

BeOne Medicines NASDAQ:ONC

Sanofi NASDAQ:SNY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools